Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab

Authors

Jacob R. Kilgore MD, Marshall University Joan C. Edwards School of MedicineFollow
James C. Curry, Marshall University Joan C. Edwards School of MedicineFollow
Shane E. Cook MD, Boone Memorial HospitalFollow

Author Credentials

Jacob Randal Kilgore, MD Joan C. Edwards School of Medicine at Marshall University kilgore30@marshall.edu James Clayton Curry, MS4 Joan C. Edwards School of Medicine at Marshall University Curry162@marshall.edu Shane E. Cook, MD Boone Memorial Hospital Drcook.se@gmail.com

Author ORCID Identifier

0000-0003-0917-2792

Keywords

psoriasis, Guselkumab, Tremfya, Lentigines

Disciplines

Dermatology | Medicine and Health Sciences | Other Pharmacy and Pharmaceutical Sciences

Abstract

Eruptive lentigines in the area of resolving psoriatic plaques has been well documented in the literature following successful treatment with multiple therapies. This is historically associated with light treatment but has been expanded to include other therapies such as anti-tumor necrosis factor therapies and, more recently, some biologics⁵. Guselkumab (Tremfya) is an IgG1λ monoclonal antibody used in the treatment of plaque psoriasis with only one case of eruptive lentigines confined to resolving psoriatic plaques (ELRP) noted as a side effect. We present the second such case of ELRP associated with successful treatment of plaque psoriasis with Guselkumab, as it is important to document potential side effects of medications regardless of their severity.

Recommended Citation

Kilgore JR, Curry JC, Cook SE. Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab. Marshall J Med. 2023; 9(2) DOI: https://doi.org/10.33470/2379-9536.1390.